newsfilter
← Latest News
GlobeNewswire·

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Arcutis Biotherapeutics granted 143,500 restricted stock units & 37,000 stock options to 24 newly hired employees as a material inducement under the 2022 Inducement Plan.
  • The awards were approved by the Compensation Committee with an August 3, 2026 grant date in compliance with Nasdaq Listing Rule 5635(c)(4).
  • RSUs will vest over four years with 25% vesting annually on each anniversary, contingent on continued employment.
  • Stock options vest over four years, starting with 25% at the one-year anniversary followed by 36 equal monthly installments, subject to continuous employment.
  • Options have a ten-year term & an exercise price of $25.94 per share, matching the Nasdaq closing price on August 3, 2026.
  • Arcutis is a commercial-stage company focused on advanced topicals for chronic inflammatory skin diseases.
  • The press release includes standard forward-looking statement disclaimers regarding risks & uncertainties affecting future results.